News articles about Chemours (NYSE:CC) have been trending somewhat positive on Sunday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chemours earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the specialty chemicals company an impact score of 45.9759737901565 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
Shares of Chemours stock traded down $1.40 on Friday, reaching $48.68. The company’s stock had a trading volume of 1,634,974 shares, compared to its average volume of 1,902,504. The stock has a market capitalization of $8,885.27, a PE ratio of 12.74, a price-to-earnings-growth ratio of 0.58 and a beta of 2.95. Chemours has a 52-week low of $34.70 and a 52-week high of $58.08. The company has a debt-to-equity ratio of 4.74, a current ratio of 2.12 and a quick ratio of 1.55.
Chemours (NYSE:CC) last posted its quarterly earnings data on Wednesday, February 14th. The specialty chemicals company reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.24. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Chemours had a return on equity of 115.54% and a net margin of 12.06%. The business’s revenue was up 19.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 earnings per share. equities research analysts anticipate that Chemours will post 5.37 EPS for the current fiscal year.
Several research analysts recently weighed in on CC shares. TheStreet upgraded Chemours from a “c+” rating to a “b-” rating in a research report on Monday, April 2nd. Morgan Stanley started coverage on Chemours in a research report on Tuesday, January 30th. They set an “equal weight” rating and a $57.50 price target for the company. ValuEngine cut Chemours from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. BMO Capital Markets started coverage on Chemours in a research report on Tuesday, March 27th. They set an “outperform” rating and a $68.00 price target for the company. Finally, Zacks Investment Research upgraded Chemours from a “hold” rating to a “strong-buy” rating and set a $58.00 price target for the company in a research report on Wednesday, February 21st. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $58.86.
In other news, VP Mark Newman sold 29,381 shares of Chemours stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $49.19, for a total value of $1,445,251.39. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Paul Kirsch sold 13,770 shares of Chemours stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $50.01, for a total value of $688,637.70. Following the completion of the sale, the insider now directly owns 63,093 shares in the company, valued at $3,155,280.93. The disclosure for this sale can be found here. 1.75% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/chemours-cc-earns-news-sentiment-score-of-0-18.html.
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.